493 related articles for article (PubMed ID: 32320027)
1. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A
JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
Mazzetti A; Moro L; Gerloni M; Cartwright M
J Drugs Dermatol; 2019 Jun; 18(6):570. PubMed ID: 31251550
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study.
Mazzetti A; Moro L; Gerloni M; Cartwright M
J Drugs Dermatol; 2019 Jun; 18(6):563. PubMed ID: 31251549
[TBL] [Abstract][Full Text] [Related]
4. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris.
Eichenfield L; Hebert A; Gold LS; Cartwright M; Fragasso E; Moro L; Mazzetti A
J Am Acad Dermatol; 2020 Aug; 83(2):477-485. PubMed ID: 32348828
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris.
Hebert A; Eichenfield L; Thiboutot D; Stein Gold L; Vassileva S; Mihaylova Y; Cartwright M; Moro L; Fragasso E; Han J; Squittieri N; Mazzetti A
J Drugs Dermatol; 2023 Feb; 22(2):174-181. PubMed ID: 36745367
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris.
Eichenfield LF; Hebert AA; Gold LS; Cartwright M; Moro L; Han J; Squittieri N; Mazzetti A
J Drugs Dermatol; 2023 Aug; 22(8):810-816. PubMed ID: 37556524
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials.
Alkhodaidi ST; Al Hawsawi KA; Alkhudaidi IT; Magzoub D; Abu-Zaid A
Dermatol Ther; 2021 Jan; 34(1):e14609. PubMed ID: 33258536
[TBL] [Abstract][Full Text] [Related]
8. Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris.
Eichenfield LF; Gold LS; Han J; Hebert AA; Mazzetti A; Moro L; Squittieri N; Thiboutot D
J Drugs Dermatol; 2024 Jan; 23(1):1278-1283. PubMed ID: 38206145
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.
Tan J; Thiboutot D; Popp G; Gooderham M; Lynde C; Del Rosso J; Weiss J; Blume-Peytavi U; Weglovska J; Johnson S; Parish L; Witkowska D; Sanchez Colon N; Alió Saenz A; Ahmad F; Graeber M; Stein Gold L
J Am Acad Dermatol; 2019 Jun; 80(6):1691-1699. PubMed ID: 30802558
[TBL] [Abstract][Full Text] [Related]
10. Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne.
Kalabalik-Hoganson J; Frey KM; Ozdener-Poyraz AE; Slugocki M
Ann Pharmacother; 2021 Oct; 55(10):1290-1296. PubMed ID: 33533262
[TBL] [Abstract][Full Text] [Related]
11. Clascoterone cream (1%) topical androgen receptor inhibitor for the treatment of acne in patients 12 years and older.
Gold M
Expert Rev Clin Immunol; 2021 Apr; 17(4):301-308. PubMed ID: 33616473
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
[TBL] [Abstract][Full Text] [Related]
13. Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone.
Bhatia N; Eichenfield LF; Mazzetti A; Moro L; Squittieri N; Hebert AA
J Drugs Dermatol; 2024 Jun; 23(6):433-437. PubMed ID: 38834220
[TBL] [Abstract][Full Text] [Related]
14. Individual Article: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne.
Peterson H; Kircik L; Armstrong AW
J Drugs Dermatol; 2023 Jun; 22(6):SF350992s7-SF350992s14. PubMed ID: 37276168
[TBL] [Abstract][Full Text] [Related]
15. Clascoterone: First Approval.
Dhillon S
Drugs; 2020 Nov; 80(16):1745-1750. PubMed ID: 33030710
[TBL] [Abstract][Full Text] [Related]
16. Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex.
Kircik LH; Gold LS; Beer K; Tan J; Baldwin H; Guenin E; Kang R; Varughese J
J Drugs Dermatol; 2020 Aug; 19(8):777-783. PubMed ID: 32845584
[TBL] [Abstract][Full Text] [Related]
17. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
[TBL] [Abstract][Full Text] [Related]
18. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
Stein Gold L; Pariser DM; Guenin E
J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
[TBL] [Abstract][Full Text] [Related]
19. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
Han G; Armstrong AW; Desai SR; Guenin E
J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
[TBL] [Abstract][Full Text] [Related]
20. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
